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ABSTRACT
Tetraethyidicyanoborane pyrophosphate (2) and 3’-(diethylphosphite-cyanoborano)-5’-dimethoxytrityI-N4-
benzoyl-deoxycytidine (3) have been synthesized in 70% and 76% yields, respectively. The compatibility of
the substituted boranophosphates with common protecting groups is hereby demonstrated.
Boron containing biologically active compounds, such as nucleosides and nucleotides
1.6 and amino acids
7-9
are important due to their potential therapeutic activity, research and diagnostic applications. Many boron
containing compounds have shown promising activity as anticancer,
1" TM -
antiinflammatory,
3 and
antiosteoporotic 3agents. Oligonucleotides in which a non-bridgipg oxygen atom is replaced by a borane
(BH3) group are a very important class of modified nucleic acids.
1. 3, 14.16 The BH3 group is isoelectronic with
oxygen in natural oligonucleotides and isoelectronic and isostructural with the oligonucleotide methyl
phosphonates, which are nuclease resistant. On the other hand, the c-borano triphosphates are good
substrates for DNA polymerases and incorporation of boranophosphates into DNA causes an increase in the
resistance to exo- and endonucleases -’ 17a as compared to non-modified DNA. There are also notable
applications of the c-borano triphosphates in PCR sequencing
17a and nucleic acid detection.
17b
Figure 1. Isoelectronic Nucleic Acid Backbones
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Although considerable effort and progress has been made with the boranophosphate linkage,
numerous limitations with this moiety still exist, especially in chemical syntheses. Thus, the highly reducing
borane group causes base degradation and incompatibility with commonly used protecting groups in
modified oligonucleotide synthesis.
3a)" 18a Likewise, the BH3 moiety has severe toxicity implications.
Sb We
have been intensively investigating the attachment of substituted boranes such as BH_X, where X COOR,
C(O)NR’H, CN, etc., to phosphorus in biologically important molecules. Here we report the use of
substituted boranes in the syntheses of boronated pyrophosphates and nucleic acids which promises to greatly
expand the scope of this class of nucleic acids.
Reaction of the potassium salt" of diethyiphosphite-cyanoborane with methanesulfonyl chloride
gave tetraethyldicyanoborane pyrophosphate 2 as shown in Scheme 1. Purification was achieved b. column
.1 chromatography using ethyl acetate as an eluent. The yields range from 65-71% Analysis by P NMR
spectroscopy showed a quartet of triplet at 3 80.2 ppm corresponding to the cyanoborane phosphate group.
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The preparation of K (RO)2PBH3" salt and analogous tetramethyl-boranopyrophosphate was previously
reported by Imamato et. al. 22, and demonstrated to have good versatility in the preparation of
boranophosphate compounds. However, these species may still be of limited use because of the presence of
highly reducing BH3 moiety. Convincing evidence that subst#uted boranes with less reducing power can
mitigate many of the problems caused by the BH3 group is demonstrated by the synthesis of 3. In this
instance, the 5’-trityl protected group is retained in the synthesis whereas with borane unit, BH3, it is
completely removed.
3,.8 Thus, the reaction of 5’-protected 2’-deoxycytidine, Benzoyl (Bz), dimethoxytrityl
(DMT) deoxycytidine, with pyrophosphate 2 (Scheme 2), followed by evaporation of the solvent resulted in
the formation of 3’-(diethylphosphite-cyanoborano)- 5’-dimethoxytrityl-N4-benzoyl-deoxycytidine 3. This
crude product was purified by flash chromatography and obtained in 75% yield (by H NMR) 23. Analysis by
3p NMR spectroscopy showed a quartet of triplet at t5 68.12 ppm corresponding to the cyanoborane
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phosphate group. The *B NMR spectrum of 2 contained a doublet of triplet at 3- 39.63 ppm corresponding
to cyanoborane phosphate group. IR spectrum of the purified product showed two broad bands at 2762 and
2701 cm*, corresponding to B-H stretch, and a sharp peak at 2295 cm is consistent with CN stretch. The
DMT protecting group and boranophosphate were incompatible in previous synthetic procedures.
3a’8
However, with the use of the less reducing cyanoborane, the DMT nucleoside was isolated in 75% yield
using the procedure described here. Substituted boranes are less reducing than BH3 moiety and should also
inhibit the base degradation. In fact, cyanoborane adducts of various N positions of purine and pyrimidine
nucleosides have been prepared with the bases not reduced or degraded.
3b)
Thus, in view of the great importance of phosphate moieties (pyrophosphates, nucleic acids, etc.) in
biological processes, the availability of boronated phosphates, such as 2 and 3, is expected to be of
considerable interest. Work on a variety of such species is currently underway in our laboratories.
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